Financial Contrast: Osiris Therapeutics (OSIR) versus Tetralogic Pharmaceuticals Corp (TLOG)

Osiris Therapeutics (NASDAQ: OSIR) and Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation.

Insider & Institutional Ownership

19.9% of Osiris Therapeutics shares are owned by institutional investors. Comparatively, 2.7% of Tetralogic Pharmaceuticals Corp shares are owned by institutional investors. 44.6% of Osiris Therapeutics shares are owned by insiders. Comparatively, 24.0% of Tetralogic Pharmaceuticals Corp shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Osiris Therapeutics and Tetralogic Pharmaceuticals Corp, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Osiris Therapeutics 0 0 0 0 N/A
Tetralogic Pharmaceuticals Corp 0 0 0 0 N/A

Profitability

This table compares Osiris Therapeutics and Tetralogic Pharmaceuticals Corp’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Osiris Therapeutics -2.60% -3.13% -2.59%
Tetralogic Pharmaceuticals Corp N/A N/A -73.81%

Risk & Volatility

Osiris Therapeutics has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Tetralogic Pharmaceuticals Corp has a beta of 3, suggesting that its share price is 200% more volatile than the S&P 500.

Earnings and Valuation

This table compares Osiris Therapeutics and Tetralogic Pharmaceuticals Corp’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Osiris Therapeutics $86.60 million 2.31 $4.41 million N/A N/A
Tetralogic Pharmaceuticals Corp N/A N/A -$21.14 million ($1.76) -0.01

Osiris Therapeutics has higher revenue and earnings than Tetralogic Pharmaceuticals Corp.

Summary

Osiris Therapeutics beats Tetralogic Pharmaceuticals Corp on 5 of the 8 factors compared between the two stocks.

About Osiris Therapeutics

Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing. The Company’s products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company’s BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.

About Tetralogic Pharmaceuticals Corp

TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company’s histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.

Receive News & Ratings for Osiris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osiris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply